25 May 2016 in Journal of Medical Internet Research
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet
9 September 2021 in Pharmacoepidemiology and Drug Safety
Objectives: To provide information about the off‐label rate of all drug prescriptions in neonates and infants up to 1 year in Spain. Also, to analyse the off‐label prescription of medicines under current practice in this age group according to different evidence sources.Study design: A five‐year (2015–2019) exploratory observational study about off‐label prescription in neonates and infants (0 to 1 year) at primary health care in Spain. All drug prescriptions in this age group were analysed and classified according to their labelling in off‐label or on‐label. The drugs prescribed off‐label were subsequently reviewed in national formularies and other databases to assess its evidence of use beyond what is recommended in the Summary of Product Characteristics (SmPC).Results: On average 34.50% of total prescriptions were prescribed off‐label according to the SmPC. 17.93% of total prescriptions in neonates and infants up to 1 year old were not based on clinical evidence from SmPC, Pediamécum, BNF or DailyMed. In more than 88% of cases, off‐label use was related to the posology section of the SmPC, followed by the therapeutic indications and contraindications sections, in 35.20% and 24.10% of cases, respectively. Almost 13% of off‐label drugs were over‐the‐counter. Salbutamol followed by topical tobramycin and colecalciferol were the drugs most prescribed off‐label.Conclusions: Off‐label use of drugs remains as an important public health concern, especially for neonates and infants up to 1 year, who receive the greatest proportion of off‐label prescriptions. The evidence‐based off‐label prescription is a widespread practice that has shown a stable trend during the 5‐year study period providing also a certain extent of flexibility to paediatricians in some therapeutic decisions.
17 January 2019 in BMJ Open
Objectives To assess the degree of readability and the length of the package leaflets of biosimilars. Setting The package leaflets analysed were downloaded from the European Medicines Agency (EMA) website. Participants The study sample included the package leaflets written in English of all the biosimilars that were authorised by the EMA on 31 August 2017, and whose content was available via the internet on that date (n=35). Design This was a cross-sectional analytical study. The readability of the package leaflets of all biosimilars authorised by the EMA in August 2017 was determined applying the Flesch and Flesch-Kincaid formulas. The influence of the following variables on the readability and length was also analysed: package leaflet section, type of biosimilar, date of first authorisation of the biosimilar and type of medicine. Results A considerable variation of the package leaflets length was found (3154±803). The readability of all the package leaflets overtook the recommended value for health-related written materials taking into account Flesch-Kincaid Index, and none of the package leaflets were easy to understand according to the Flesch Index. Statistically significant differences (p<0.05) were observed between the sections of package leaflets in readability indices and length. The most difficult sections to understand were those related with the therapeutic indication of medicine and the possible side effects. Conclusions Package leaflets for authorised biosimilars may not fulfil the function for which they were designed. The competent organisations could be informed about the possible negative effect on the use of this type of medicines.